In vitro investigation of anticancer efficacy of carboplatin-loaded PEGylated nanoliposome particles on brain cancer cell lines
Source abstract
Abstract
Recently, designing a nanocarrier for carboplatin with high retention power and entrapment efficiency and its corresponding impact has sparked a heated debate. The aim of this study was to investigate the cytotoxic efficacy of the biodegradable nanocarrier loaded with carboplatin. This study focuses on (i) characterization, (ii) in vitro drug release evaluation, and (iii) cytotoxicity of liposome nanoparticles (NPs) loaded with carboplatin. The reverse-phase evaporation was used to synthesize nanoparticles and determine specifications including shape morphology, particle size, drug release rate, polydispersity index (PDI), stability, and zeta potential of prepared formulation. Furthermore, A172 and C6 glioblastoma cell lines were used to determine the efficacy of nanodrug using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. NPs had an average size of 240.5 nm and zeta potential of − 25.8 mV. Drug loading and encapsulation efficiency of NPs were 2.65% and 71.45%, respectively. Moreover, entrapment efficiency and drug release rate increase in a time-dependent manner. The results reveal that the preparation method and PEGylation have a positive effect of the properties of NPs and the efficiency of encapsulation and loading rate. Results from stability study reported that using PEGylation helps to improve characteristics of NPs and results in minimal changes in their properties over the time. In addition, our data demonstrate that carboplatin cytotoxicity correlates with drug concentration which was considerably increased in NPs. PEGylated NPs have enhanced cytotoxicity against glioblastoma cell lines compared with free drug. Overall, our evaluation has shown that the PEGylated nanoliposome particles loaded with carboplatin hold high potential for nanoparticle-based therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. Andrieux K, Couvreur P (2009) Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood–brain barrier. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:463–47410.1002/wnan.5 ↗
2. Arshad A, Yang B, Bienemann AS, Barua NU, Wyatt MJ, Woolley M, Johnson DE, Edler KJ, Gill SS (2015) Convection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastoma. PLoS One 10:e013226610.1371/journal.pone.0132266 ↗
3. Bangham AD, Horne RW (1964) Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 8:660–66810.1016/S0022-2836(64)80115-7 ↗
4. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29–4510.1016/j.pharmthera.2004.08.001 ↗
5. Breen W, Bancos I, Young WF, Bible KC, Laack NN, Foote RL, Hallemeier CL (2018) External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3:25–2910.1016/j.adro.2017.11.002 ↗
6. Cooper ER (2010) Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Release 141:300–30210.1016/j.jconrel.2009.10.006 ↗
7. Cosco D, Paolino D, Muzzalupo R, Celia C, Citraro R, Caponio D, Picci N, Fresta M (2009) Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdevices 11:1115–112510.1007/s10544-009-9328-2 ↗
8. Crowley LC, Marfell BJ & Waterhouse NJ (2016) Analyzing cell death by nuclear staining with Hoechst 33342. Cold Spring Harbor Protocols, 2016, pdb.prot08720510.1101/pdb.prot087205 ↗
9. Delaney TF, Haas RLM (2016) Innovative radiotherapy of sarcoma: proton beam radiation. Eur J Cancer 62:112–12310.1016/j.ejca.2016.04.015 ↗
10. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology 14:v1–v4910.1093/neuonc/nos218 ↗
11. Dorsey JF, Hollander AB, Alonso-Basanta M, Macyszyn L, Bohman L-E, Judy KD, Maity A, Lee JYK, Lustig RA, Phillips PC, Pruitt AA (2014) 66—Cancer of the central nervous system. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE (eds) Abeloff’s clinical oncology (fifth edition). Content Repository Only, Philadelphia
12. Ebrahimifar M, Nili-Ahmadabadi A, Akbarzadeh A, Shahemabadi HE, Hasanzadegan M, Moradi-Sardareh H, Madadizadeh H, Rezaee-Diyan J (2017) Preparation, characterization and cytotoxic effects of pegylated nanoliposomal containing carboplatin on ovarian cancer cell lines. Indian J Clin Biochem 32:230–23410.1007/s12291-016-0596-3 ↗
13. Ebrahimifar M, Hasanzadegan Roudsari M, Kazemi SM, Ebrahimi Shahmabadi H, Kanaani L, Alavi SA, Izadi Vasfi M Enhancing effects of curcumin on cytotoxicity of paclitaxel, methotrexate and vincristine in gastric cancer cells. Asian Pac J Cancer Prevent 18:65–68
14. Gozde U, Ufuk G (2018) Smart drug delivery systems in cancer therapy. Curr Drug Targets 19:202–212
15. Hamelers IHL, Van Loenen E, Staffhorst RWHM, De Kruijff B, De Kroon AIPM (2006) Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol Cancer Ther 5:2007–201210.1158/1535-7163.MCT-06-0089 ↗
16. Honary S & Zahir F (2013) Effect of zeta potential on the properties of nano-drug delivery systems—a review (part 1) Tropical Journal of Pharmaceutical 12 (2): 265–27310.4314/tjpr.v12i2.19 ↗
17. Jafari M, Soltani M, Naahidi S, Karunaratne N & Chen P (2012) Nonviral approach for targeted nucleic acid delivery, nonviral approach for targeted nucleic acid delivery, Nonviral Approach for Targeted Nucleic Acid Delivery, Current Medicinal Chemistry 19(2):197–208 https://doi.org/10.2174/09298671280341414110.2174/092986712803414141 ↗
18. Kawai F (2002) Microbial degradation of polyethers. Appl Microbiol Biotechnol 58:30–3810.1007/s00253-001-0850-2 ↗
19. Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 49:6288–630810.1002/anie.200902672 ↗
20. Lee BK, Yun YH, Park K (2015) Smart nanoparticles for drug delivery: boundaries and opportunities. Chem Eng Sci 125:158–16410.1016/j.ces.2014.06.042 ↗
21. Mayer RS (2014) 55—rehabilitation of individuals with cancer. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE (eds) Abeloff’s clinical oncology (fifth edition). Content Repository Only! Philadelphia
22. Moreno AC, Frank SJ, Garden AS, Rosenthal DI, Fuller CD, Gunn GB, Reddy JP, Morrison WH, Williamson TD, Holliday EB, Phan J, Blanchard P (2019) Intensity modulated proton therapy (IMPT)—the future of IMRT for head and neck cancer. Oral Oncol 88:66–7410.1016/j.oraloncology.2018.11.015 ↗
23. Müller RH, Lherm C, Herbert J, Couvreur P (1990) In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 11:590–59510.1016/0142-9612(90)90084-4 ↗
24. Otsuka H, Nagasaki Y, Kataoka K (2012) PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 64(Supplement):246–25510.1016/j.addr.2012.09.022 ↗
25. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J NeuroImmune Pharmacol 1:223–23610.1007/s11481-006-9025-3 ↗
26. Ramirez SH, Haskó J, Skuba A, Fan S, Dykstra H, Mccormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son Y-J, Persidsky Y (2012) Activation of cannabinoid receptor 2 attenuates leukocyte–endothelial cell interactions and blood–brain barrier dysfunction under inflammatory conditions. J Neurosci 32:4004–401610.1523/JNEUROSCI.4628-11.2012 ↗
27. Rosenzweig KE, Dladla N, Schindelheim R, Sim SE, Braban LE, Venkatraman ES, Leibel SA (2001) Three-dimensional conformal radiation therapy (3D-CRT) for early-stage non–small-cell lung cancer. Clin Lung Cancer 3:141–14410.3816/CLC.2001.n.025 ↗
28. Sathyamoorthy N, Dhanaraju MD, Devendiran S & Heera B (2017) Influence of surface charge on the in vitro protein adsorption and cell cytotoxicity of paclitaxel loaded poly(Îμ-caprolactone) nanoparticles. Bulletin of Faculty of Pharmacy, Cairo University, 55, 249–25810.1016/j.bfopcu.2017.06.003 ↗
29. Sefidgar M, Soltani M, Raahemifar K, Sadeghi M, Bazmara H, Bazargan M, Mousavi Naeenian M (2015) Numerical modeling of drug delivery in a dynamic solid tumor microvasculature. Microvasc Res 99:43–5610.1016/j.mvr.2015.02.007 ↗
30. Shahzad MMK, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12:148–15210.1016/j.drup.2009.09.001 ↗
31. Soltani M, Chen P (2012) Effect of tumor shape and size on drug delivery to solid tumors. J Biol Eng 6:410.1186/1754-1611-6-4 ↗
32. Stojanovska V, Sakkal S, Nurgali K (2015) Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am J Physiol Gastrointest Liver Physiol 308:G223–G23210.1152/ajpgi.00212.2014 ↗
33. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–99610.1056/NEJMoa043330 ↗
34. Tan J, Shah S, Thomas A, Ou-Yang HD, Liu Y (2013) The influence of size, shape and vessel geometry on nanoparticle distribution. Microfluid Nanofluid 14:77–8710.1007/s10404-012-1024-5 ↗
35. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–145810.1016/S1359-6446(05)03575-0 ↗
36. Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P, Rinaudo M, Schué F (2012) Terminology for biorelated polymers and applications (IUPAC recommendations 2012). Pure Appl Chem 84:377–41010.1351/PAC-REC-10-12-04 ↗
37. Wang X, Yang L, Chen Z, Shin Dong M (2008) Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 58:97–11010.3322/CA.2007.0003 ↗
38. Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63:185–19810.1146/annurev-med-040210-162544 ↗
39. Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel. Drug Resist Updat 7:227–23210.1016/j.drup.2004.08.002 ↗